An immune system drug may help prevent or slow complications in a type of multiple sclerosis known as secondary progressive MS, a new study finds. The medication is called rituximab, which ...

According to trial results, rituximab helped lower relapse risk in MS patients compared with patients receiving the standard treatment drug dimethyl fumarate. There are four main types of MS ...

It was the late ’90s and UCSF Neurology Professor Stephen Hauser, MD, and team had applied for federal funding for the first clinical trial of the new medicine, rituximab, as a potential MS treatment.

For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos ...

About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...

Opens in a new tab or window Off-label rituximab (Rituxan) led to fewer relapses over 2 years than dimethyl fumarate (Tecfidera) in people with early relapsing-remitting multiple sclerosis (MS ...

Patients with multiple sclerosis (MS) treated with the drug rituximab had a significantly lower risk of relapse compared with MS patients receiving standard treatment. This has been shown in a ...

B-cell therapy uses drugs called monoclonal antibodies to attack white blood cells known as B cells that cause nerve damage. The FDA has approved three such drugs for MS. Ocrelizumab (Ocrevus ...

It’s fallen out of favor despite its potential effectiveness for treating MS. In a 2021 study, researchers compared the drug mitoxantrone with the monoclonal antibody rituximab in people with ...

About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...